These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30860610)

  • 1. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
    Brooks KM; Sherman EM; Egelund EF; Brotherton A; Durham S; Badowski ME; Cluck DB
    Pharmacotherapy; 2019 May; 39(5):576-598. PubMed ID: 30860610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.
    Scarsi KK; Havens JP; Podany AT; Avedissian SN; Fletcher CV
    Drugs; 2020 Nov; 80(16):1649-1676. PubMed ID: 32860583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
    Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
    Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
    Park TE; Mohamed A; Kalabalik J; Sharma R
    Expert Rev Anti Infect Ther; 2015; 13(10):1195-212. PubMed ID: 26293294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
    Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
    Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.
    Psichogiou M; Poulakou G; Basoulis D; Paraskevis D; Markogiannakis A; Daikos GL
    Curr Pharm Des; 2017; 23(18):2552-2567. PubMed ID: 28356041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
    Osterholzer DA; Goldman M
    Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational HIV integrase inhibitors in phase I and phase II clinical trials.
    Han Y; Mesplède T; Wainberg MA
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1207-1213. PubMed ID: 28956664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor.
    Singh H; Kaur M; Kakkar AK; Kumar H
    Curr Clin Pharmacol; 2016; 11(2):88-94. PubMed ID: 27157040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV integrase inhibitors: 20-year landmark and challenges.
    Métifiot M; Marchand C; Pommier Y
    Adv Pharmacol; 2013; 67():75-105. PubMed ID: 23885999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
    Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
    HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors.
    Hoffmann C; Llibre JM
    AIDS Rev; 2019; 21(1):4-10. PubMed ID: 30899113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
    Kandel CE; Walmsley SL
    Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
    Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety profile of integrase strand transfer inhibitors.
    Gutierrez Mdel M; Mateo MG; Vidal F; Domingo P
    Expert Opin Drug Saf; 2014 Apr; 13(4):431-45. PubMed ID: 24597519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.